ZA200102105B - Stable concentrated insulin preparations for pulmonary. - Google Patents
Stable concentrated insulin preparations for pulmonary.Info
- Publication number
- ZA200102105B ZA200102105B ZA200102105A ZA200102105A ZA200102105B ZA 200102105 B ZA200102105 B ZA 200102105B ZA 200102105 A ZA200102105 A ZA 200102105A ZA 200102105 A ZA200102105 A ZA 200102105A ZA 200102105 B ZA200102105 B ZA 200102105B
- Authority
- ZA
- South Africa
- Prior art keywords
- pulmonary
- insulin preparations
- stable concentrated
- concentrated insulin
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801327 | 1998-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200102105B true ZA200102105B (en) | 2001-10-12 |
Family
ID=8103620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200102105A ZA200102105B (en) | 1998-10-16 | 2001-03-14 | Stable concentrated insulin preparations for pulmonary. |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP1121144B1 (xx) |
| JP (1) | JP4212240B2 (xx) |
| KR (1) | KR100617286B1 (xx) |
| CN (1) | CN1210058C (xx) |
| AT (2) | ATE277630T1 (xx) |
| AU (1) | AU758146B2 (xx) |
| BR (1) | BR9914585A (xx) |
| CA (1) | CA2346969A1 (xx) |
| CZ (1) | CZ20011134A3 (xx) |
| DE (2) | DE69901726T2 (xx) |
| DK (2) | DK1172114T3 (xx) |
| ES (2) | ES2228728T3 (xx) |
| HU (1) | HUP0104111A3 (xx) |
| IL (2) | IL142011A0 (xx) |
| NO (1) | NO323365B1 (xx) |
| PL (1) | PL197504B1 (xx) |
| PT (2) | PT1121144E (xx) |
| RU (1) | RU2218935C2 (xx) |
| TW (1) | TWI223597B (xx) |
| UA (1) | UA65636C2 (xx) |
| WO (1) | WO2000023098A1 (xx) |
| ZA (1) | ZA200102105B (xx) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| NZ519403A (en) * | 2001-06-21 | 2005-03-24 | Pfizer Prod Inc | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels |
| AU2003236201A1 (en) * | 2002-05-07 | 2003-11-11 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| WO2004075913A1 (ja) | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
| BRPI0408229A (pt) * | 2003-03-11 | 2006-02-21 | Novo Nordisk As | preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação |
| EP2264065B1 (en) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| CN101389650B (zh) * | 2005-12-28 | 2012-10-10 | 诺沃-诺迪斯克有限公司 | 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法 |
| ES2542146T3 (es) | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | Insulinas extendidas PEGiladas. |
| WO2008034881A1 (en) | 2006-09-22 | 2008-03-27 | Novo Nordisk A/S | Protease resistant insulin analogues |
| US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| EP2514412A1 (en) * | 2007-04-30 | 2012-10-24 | Novo Nordisk A/S | Highly Concentrated Insulin Solutions and Compositions |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009112583A2 (en) | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| JP5749155B2 (ja) | 2008-03-18 | 2015-07-15 | ノボ・ノルデイスク・エー／エス | プロテアーゼ安定化アシル化インスリンアナログ |
| AU2011235959C1 (en) * | 2008-06-13 | 2013-10-10 | Eli Lilly And Company | PEGylated insulin lispro compounds |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| EP3228320B1 (de) | 2008-10-17 | 2019-12-18 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| ES2607003T3 (es) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
| UY33025A (es) | 2009-11-13 | 2011-06-30 | Sanofi Aventis Deustschland Gmbh | Composicion farmaceutica que comprende un agonista de glp-1 metionina |
| MX339614B (es) | 2010-08-30 | 2016-06-02 | Sanofi - Aventis Deutschland GmbH | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. |
| BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| MX2014012096A (es) | 2012-04-11 | 2014-11-21 | Novo Nordisk As | Formulaciones de insulina. |
| CN104870469A (zh) * | 2012-12-26 | 2015-08-26 | 沃克哈特有限公司 | 药物组合物 |
| CN110354255B (zh) | 2013-04-03 | 2024-05-14 | 赛诺菲 | 通过长效胰岛素制剂治疗糖尿病 |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| US9896496B2 (en) | 2013-10-07 | 2018-02-20 | Novo Nordisk A/S | Derivative of an insulin analogue |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| ES2886837T3 (es) | 2016-12-16 | 2021-12-21 | Novo Nordisk As | Composiciones farmacéuticas que contienen insulina |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) * | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| CN1198643C (zh) * | 1996-06-20 | 2005-04-27 | 诺沃挪第克公司 | 含碳水化合物的胰岛素制品 |
| AU6611898A (en) * | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer |
| AU6611998A (en) * | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
-
1999
- 1999-10-15 ES ES01126054T patent/ES2228728T3/es not_active Expired - Lifetime
- 1999-10-15 DK DK01126054T patent/DK1172114T3/da active
- 1999-10-15 AT AT01126054T patent/ATE277630T1/de not_active IP Right Cessation
- 1999-10-15 IL IL14201199A patent/IL142011A0/xx active IP Right Grant
- 1999-10-15 EP EP99948725A patent/EP1121144B1/en not_active Expired - Lifetime
- 1999-10-15 DE DE69901726T patent/DE69901726T2/de not_active Expired - Lifetime
- 1999-10-15 BR BR9914585-5A patent/BR9914585A/pt not_active Application Discontinuation
- 1999-10-15 AT AT99948725T patent/ATE218364T1/de not_active IP Right Cessation
- 1999-10-15 EP EP01126054A patent/EP1172114B1/en not_active Expired - Lifetime
- 1999-10-15 JP JP2000576871A patent/JP4212240B2/ja not_active Expired - Fee Related
- 1999-10-15 ES ES99948725T patent/ES2177323T3/es not_active Expired - Lifetime
- 1999-10-15 KR KR1020017004702A patent/KR100617286B1/ko not_active IP Right Cessation
- 1999-10-15 PT PT99948725T patent/PT1121144E/pt unknown
- 1999-10-15 AU AU61889/99A patent/AU758146B2/en not_active Ceased
- 1999-10-15 CZ CZ20011134A patent/CZ20011134A3/cs unknown
- 1999-10-15 CA CA002346969A patent/CA2346969A1/en not_active Abandoned
- 1999-10-15 RU RU2001113271/14A patent/RU2218935C2/ru not_active IP Right Cessation
- 1999-10-15 DE DE69920767T patent/DE69920767T2/de not_active Expired - Lifetime
- 1999-10-15 PL PL347210A patent/PL197504B1/pl not_active IP Right Cessation
- 1999-10-15 WO PCT/DK1999/000556 patent/WO2000023098A1/en active IP Right Grant
- 1999-10-15 HU HU0104111A patent/HUP0104111A3/hu unknown
- 1999-10-15 PT PT01126054T patent/PT1172114E/pt unknown
- 1999-10-15 UA UA2001042148A patent/UA65636C2/uk unknown
- 1999-10-15 DK DK99948725T patent/DK1121144T3/da active
- 1999-10-15 CN CNB998122084A patent/CN1210058C/zh not_active Expired - Fee Related
- 1999-10-20 TW TW088118264A patent/TWI223597B/zh not_active IP Right Cessation
-
2001
- 2001-03-14 IL IL142011A patent/IL142011A/en not_active IP Right Cessation
- 2001-03-14 ZA ZA200102105A patent/ZA200102105B/xx unknown
- 2001-04-10 NO NO20011842A patent/NO323365B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL347210A1 (en) | Stable concentrated insulin preparations for pulmonary delivery | |
| ZA984697B (en) | Stable insulin formulations. | |
| NO20010013L (no) | Svovelsubstituerte sulfonylaminokarboksylsyre N-arylamider, deres fremstilling og anvendelse samt farmasöytiske preparater inneholdende forbindelsene | |
| NO931919L (no) | Optisk aktivt 5h-pyrrolo(3,4-b)pyrazinderivat, dets fremstilling samt farmasoeytiske preparater inneholdende derivatet | |
| ZA975470B (en) | Insulin preparations containing naci. | |
| YU68199A (sh) | Farmaceutske formulacije koje sadrže vorikonazol | |
| ATE281458T1 (de) | Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate | |
| MY114211A (en) | Powder formulations containing melezitose as a diluent | |
| DE69914934D1 (de) | Stabile wässrige insulinzubereitungen ohne phenol und kresol | |
| ZA200007415B (en) | Amino acid derivatives and drugs containing the same as the active ingredient. | |
| HRP20040171A2 (en) | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof | |
| SI0884053T1 (en) | Stable insulin formulations | |
| ZA200303113B (en) | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them. | |
| WO2004058186A3 (en) | Formulations for pulmonary delivery | |
| HUP9903649A3 (en) | Taxane derivatives, the preparation thereof and medical formulations containing them | |
| ZA9997B (en) | Stabilization of Lipid: DNA Formulations during Nebulization. | |
| HUP0102226A3 (en) | Hyperforin derivatives, the use thereof and formulations containing them | |
| IL140127A0 (en) | Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof | |
| Kim | Applications of Terahertz Opto-Electronics | |
| AU3836500A (en) | 2,2-disubstituted cyclic ether derivatives and hair tonics containing the same | |
| HU0002156D0 (en) | Novel piperazinyl alkylthio pyrimidinyl derivatives, pharmaceutical compositions containing such active ingredients and process for producing the active ingredients | |
| SI1086071T1 (sl) | Derivati hiperforina, njihova uporaba in farmacevtske oblike, ki jih vsebujejo |